Lymphatic muscle cell ion channel modulation effects on lymphatic contractility
We previously showed that ion channel modulation in LMC can enhance lymphatic contractility in isolated vessel studies. L-type calcium channel agonist BayK-1884 (BayK) increases the plateau phase of the spontaneous action potential that triggers LMC contraction. KATP channel blocker Glib activates quiescent non-contractile LVs. Working in collaboration with Dr. Susan Thomas, lymph-draining nanoparticles were encapsulated with Bay-K and showed first ever demonstration of LV-directed therapy to improve LMC contractility and lymph transport in vivo. LV function is quantified by tracking the dynamics of the NIR signal as vessels contract and measuring LV pumping pressure in vivo. Thermosensitive PEG hydrogels developed by the Thomas lab offer sustained release (>1 wk) of the encapsulated drug, resulting in prolonged effects (at-least 15 h post-treatment).
Contact: Mohammed Amin Mohammed Ali